Analysis Of Gene Expression Profiling Of Formalin-Fixed And Paraffin-Embedded Tumor Tissues From Preclinical Models And Patient Samples In Early Phase Clinical Trials

The objective of this study was to identify gene expression biomarkers that are potentially predictive for birinapant response. Birinapant is a novel small molecule that mimics endogenous Smac (Second mitochondrial-derived activator of caspases), by activating the programmed cell death pathways that are dysregulated in cancer cells. TetraLogic and LabCorp Clinical Trials have collaborated to use gene expression profiling to discover biomarkers predictive for response to anti-tumor activity mediated by birinapant. Gene expression profiling studies have been performed using Illumina® DASL platform and qRT-PCR to profile FFPE (formalin-fixed, paraffin-embedded) samples from human tumor cell lines, patient-derived tumor xenografts, as well as archival tumor samples from patients in birinapant clinical trials.